Platelet-Rich Plasma Therapy for Patellar Tendinopathy

Sixty-six patients with PT will be randomized to one of three study arms. Subjects in Group 1
(PRP) will receive a single US-guided injection of 5 milliliters of autologous PRP into the
patellar tendon, subjects in Group 2 (DN) will undergo ultrasound guided dry needling of the
patellar tendon, and subjects in Group 3 (SH) will undergo a sham control ultrasound guided
dry needling in the subcutaneous tissue only (not intratendon) at the level of the patellar
tendon. The efficacy of the different treatment options will be assessed by pain- and
function-dependent, PT-specific Victorian Institute of Sport Assessment Patella (VISA-P)
quality of life scores, activity level scores, knee strength measurements, and conventional
and novel MRI and US imaging at baseline, 16, 32, and 52 weeks post-treatment.

Inclusion Criteria:

1. Age between 18 and 39 years

2. Chronic (>3 months) PT

3. Clinical examination consistent with PT

4. MRI or US confirmation of PT

5. Pain score of 3 or greater on a 10-point visual analogue scale

6. Self-report failure of supervised physical therapy

7. Self-report failure of at least 2 of the most common treatment options for PT (e.g.
NSAIDs, relative rest, ice and bracing).

Exclusion Criteria:

1. Inability to comply with study follow-up requirements

2. History of bleeding disorders or other hematologic conditions

3. Knee pain from other possible etiologies (e.g., degenerative joint disease, meniscal
tear, ligament injury or reconstruction)

4. Full or partial patellar tendon tear

5. Current use of anticoagulation or immunosuppressive therapy

6. Prior knee trauma requiring medical attention or surgery

7. Worker's compensation injury

8. Daily opioid use for pain

9. Contraindication to MRI.

10. Systemic diseases such as Diabetes and connective tissue diseases.

11. Prior PRP or DN procedure.

12. Women that are pregnant